Pharmacogenomic considerations in drug delivery

被引：7

作者：

Attar, M

Lee, VHL

机构：

[1] Univ So Calif, Dept Pharmaceut Sci, Los Angeles, CA 90089 USA

[2] Allergan Pharmaceut Inc, Dept Pharmacokinet & Drug Metab, Irvine, CA 92612 USA

来源：

PHARMACOGENOMICS | 2003年 / 4卷 / 04期

关键词：

drug delivery; enzymes; interindividual variability; pharmacodynamics; pharmacogenomics; pharmacokinetics; receptors; transporters;

D O I：

10.1517/phgs.4.4.443.22749

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Successful drug delivery will achieve an appropriate drug concentration at the target to elicit a desired level of response. The concentration of circulating free drug is dependent upon the pharmacokinetic processes of absorption, distribution, metabolism and elimination. The response usually results from interaction of a drug with a target protein. The genetic basis that underlies pharmacokinetic and pharmacodynamic interindividual variability is an important consideration in the design of drug delivery systems. Genetic polymorphism has been identified in drug-metabolizing enzymes, transporters and targets. Potentially, these pharmacogenomic factors can affect the concentration of free drug available for delivery and the subsequent elicited response.

引用

页码：443 / 461

页数：19

共 80 条

[1] POLYMORPHIC HYDROXYLATION OF S-MEPHENYTOIN AND OMEPRAZOLE METABOLISM IN CAUCASIAN AND CHINESE SUBJECTS [J].